Literature DB >> 25707352

Effects of antiviral medications on herpetic epithelial keratitis in mice.

Shohei Komoto1, Shiro Higaki, Masahiko Fukuda, Yoshikazu Shimomura.   

Abstract

PURPOSE: Aciclovir (ACV), valaciclovir (VACV) and famciclovir (FCV) are used for systemic infections caused by herpes virus. In Japan, only topical ACV is permitted for use against herpetic keratitis. We investigated the effectiveness of topical ACV, oral VACV and oral FCV on mouse epithelial herpetic keratitis.
METHODS: C57/BL76 mice were inoculated with HSV-1 McKrae strain in the cornea. Once infection was confirmed 4 days after inoculation, topical ACV, oral VACV and FCV were started and administered for 5 days. Control groups were given either topical or oral saline. On days 2, 4, 6 and 10 after medication started, tears, eyeballs, and trigeminal ganglia were examined using viral culture and real-time PCR.
RESULTS: Viral culture of tears detected no HSV in the topical ACV group on day 4 after administration start; with similar results for the oral VACV group on day 4; and the oral FCV group on day 6. Real-time PCR of the eyeballs showed significant decrease of HSV DNA copy number in the topical ACV group on days 4 and 6 compared to the topical saline group. Real-time PCR of the trigeminal ganglia showed significant decrease of HSV DNA copy number in the oral VACV group on days 4 and 6, and in the oral FCV group on day 6 compared to the oral saline group.
CONCLUSION: We suggest that 5-day administration of topical ACV, oral VACV and oral FCV are effective for mouse epithelial herpetic keratitis and sufficiently decrease HSV amounts in the ocular surface and eyeballs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707352     DOI: 10.1007/s10384-015-0375-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  25 in total

1.  Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.

Authors:  N M Sawtell; R L Thompson; L R Stanberry; D I Bernstein
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

2.  Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial.

Authors:  Engin Sozen; Avni Murat Avunduk; Nurettin Akyol
Journal:  Chemotherapy       Date:  2005-12-09       Impact factor: 2.544

3.  Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits.

Authors:  J M Loutsch; B Sainz; M E Marquart; X Zheng; P Kesavan; S Higaki; J M Hill; R Tal-Singer
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Activity of penciclovir in antiviral assays against herpes simplex virus.

Authors:  T H Bacon; B A Howard; L C Spender; M R Boyd
Journal:  J Antimicrob Chemother       Date:  1996-02       Impact factor: 5.790

5.  Effects of anti herpetic drugs on mice with herpetic epithelial keratitis after reactivation of herpes simplex virus type 1.

Authors:  Motoki Itahashi; Shiro Higaki; Yoshikazu Shimomura
Journal:  Semin Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 1.975

6.  Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.

Authors:  E G Romanowski; S P Bartels; Y J Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-02       Impact factor: 4.799

7.  Gene expression profiling in the HSV-1 latently infected mouse trigeminal ganglia following hyperthermic stress.

Authors:  Shiro Higaki; Bryan Gebhardt; Walter Lukiw; Hilary Thompson; James Hill
Journal:  Curr Eye Res       Date:  2003 Mar-Apr       Impact factor: 2.424

8.  Cold stress-induced recurrences of herpetic keratitis in the squirrel monkey.

Authors:  E D Varnell; H E Kaufman; J M Hill; H W Thompson
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-05       Impact factor: 4.799

Review 9.  Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.

Authors:  D J Purifoy; L M Beauchamp; P de Miranda; P Ertl; S Lacey; G Roberts; S G Rahim; G Darby; T A Krenitsky; K L Powell
Journal:  J Med Virol       Date:  1993       Impact factor: 2.327

Review 10.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.